share_log

Virpax Pharmaceuticals | 10-Q: Q3 2024 Earnings Report

Virpax Pharmaceuticals | 10-Q: Q3 2024 Earnings Report

Virpax制药 | 10-Q：2024财年三季报
美股SEC公告 ·  11/14 17:07

Moomoo AI 已提取核心信息

Virpax Pharmaceuticals, Inc. (Virpax), a preclinical-stage pharmaceutical company, reported financial results for the quarter ended September 30, 2024. The company experienced a net loss of $2,006,456 for the quarter, compared to a net loss of $5,994,498 for the same period in 2023. Operating expenses totaled $1,924,354, a significant decrease from $6,115,138 in the previous year, primarily due to reduced legal expenses following the settlement of a lawsuit. Research and development expenses also decreased to $1,143,396 from $1,495,619 year-on-year. The company's cash position as of September 30, 2024, was $17,229, down from $9,141,512 at the end of 2023. Virpax's financial performance reflects ongoing investments in its drug development pipeline, including its lead product candidate Probudur, a non-opioid pain management treatment. The company's future plans include continuing clinical trials and seeking additional funding to support operations and product development. Virpax's ability to continue as a going concern is dependent on raising additional capital, which may include equity offerings, debt financings, or strategic partnerships.
Virpax Pharmaceuticals, Inc. (Virpax), a preclinical-stage pharmaceutical company, reported financial results for the quarter ended September 30, 2024. The company experienced a net loss of $2,006,456 for the quarter, compared to a net loss of $5,994,498 for the same period in 2023. Operating expenses totaled $1,924,354, a significant decrease from $6,115,138 in the previous year, primarily due to reduced legal expenses following the settlement of a lawsuit. Research and development expenses also decreased to $1,143,396 from $1,495,619 year-on-year. The company's cash position as of September 30, 2024, was $17,229, down from $9,141,512 at the end of 2023. Virpax's financial performance reflects ongoing investments in its drug development pipeline, including its lead product candidate Probudur, a non-opioid pain management treatment. The company's future plans include continuing clinical trials and seeking additional funding to support operations and product development. Virpax's ability to continue as a going concern is dependent on raising additional capital, which may include equity offerings, debt financings, or strategic partnerships.
Virpax制药公司（Virpax）是一家处于临床前阶段的制药公司，报告了截至2024年9月30日的季度财务结果。该公司本季度净损失为$2,006,456，而2023年同期净损失为$5,994,498。营业费用总计$1,924,354，与上一年的$6,115,138相比显著减少，主要是由于解决诉讼问题后法律费用减少所致。研发费用也同比减少至$1,143,396，而去年同期为$1,495,619。截至2024年9月30日，公司现金余额为$17,229，较2023年底的$9,141,512有所下降。Virpax的财务表现反映了持续投资于其药物开发管线，包括其主打产品候选药Probudur，一种非阿片类疼痛管理治疗药物。该公司未来计划包括继续临床试验，并寻求额外资金支持运营和产品开发。Virpax继续作为一个持续存在的公司的能力取决于筹集额外资金，这可能包括股权发行、债务融资或战略伙伴关系。
Virpax制药公司（Virpax）是一家处于临床前阶段的制药公司，报告了截至2024年9月30日的季度财务结果。该公司本季度净损失为$2,006,456，而2023年同期净损失为$5,994,498。营业费用总计$1,924,354，与上一年的$6,115,138相比显著减少，主要是由于解决诉讼问题后法律费用减少所致。研发费用也同比减少至$1,143,396，而去年同期为$1,495,619。截至2024年9月30日，公司现金余额为$17,229，较2023年底的$9,141,512有所下降。Virpax的财务表现反映了持续投资于其药物开发管线，包括其主打产品候选药Probudur，一种非阿片类疼痛管理治疗药物。该公司未来计划包括继续临床试验，并寻求额外资金支持运营和产品开发。Virpax继续作为一个持续存在的公司的能力取决于筹集额外资金，这可能包括股权发行、债务融资或战略伙伴关系。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间